Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4 in COPD

Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig

Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: OTR Therapeutics Series A $100 million backed by Pfizer Ventures

Lucid Diligence Brief: OTR Therapeutics Series A $100 million backed by Pfizer…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+

Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+ Professional audiences…


Privacy Preference Center